| pubmed-article:21029821 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0001779 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0010068 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0020443 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0286651 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C1881878 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C0439234 | lld:lifeskim |
| pubmed-article:21029821 | lifeskim:mentions | umls-concept:C1532737 | lld:lifeskim |
| pubmed-article:21029821 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:21029821 | pubmed:dateCreated | 2010-10-29 | lld:pubmed |
| pubmed-article:21029821 | pubmed:abstractText | Higher than 80% of coronary heart disease-related mortality occurs in patients ?65 years of age. Guidelines recommend low-density lipoprotein (LDL) cholesterol targets for these at-risk patients; however, few clinical studies have evaluated lipid-lowering strategies specifically in older adults. This multicenter, 12-week, randomized, double-blind, parallel-group trial evaluated the efficacy and safety of the usual starting dose of ezetimibe/simvastatin (10/20 mg) versus atorvastatin 10 or 20 mg and the next higher dose of ezetimibe/simvastatin (10/40 mg) versus atorvastatin 40 mg in 1,289 hypercholesterolemic patients ?65 years of age with or without cardiovascular disease. Patients randomized to ezetimibe/simvastatin had greater percent decreases in LDL cholesterol (-54.2% for 10/20 mg vs -39.5% and -46.6% for atorvastatin 10 and 20 mg, respectively; -59.1% for 10/40 mg vs -50.8% for atorvastatin 40 mg; p <0.001 for all comparisons) and the number attaining LDL cholesterol <70 mg/dl (51.3% for 10/20 mg, 68.2% for 10/40 mg) and <100 mg/dl (83.6% for 10/20 mg; 90.3% for 10/40 mg) was significantly larger compared to those receiving atorvastatin for all prespecified dose comparisons (p <0.05 to <0.001). A significantly larger percentage of high-risk patients achieved LDL cholesterol <70 mg/dl on ezetimibe/simvastatin 10/20 mg (54.3%) versus atorvastatin 10 mg (10.9%, p <0.001) or 20 mg (28.9%, p <0.001) and ezetimibe/simvastatin 10/40 mg (69.2%) versus atorvastatin 40 mg (38.2%, p <0.001), and a significantly larger percentage of intermediate-risk patients achieved LDL cholesterol <100 mg/dl on ezetimibe/simvastatin 10/20 mg (82.1%) versus atorvastatin 10 mg (59.3%, p <0.05). Improvements in non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and lipoprotein ratios were significantly greater with ezetimibe/simvastatin than atorvastatin for all comparisons (p <0.01 to <0.001). High-density lipoprotein cholesterol and triglyceride results were variable. All treatments were generally well tolerated. In conclusion, ezetimibe/simvastatin provided significantly greater improvements in key lipid parameters and higher attainment of LDL cholesterol targets than atorvastatin, with comparable tolerability. | lld:pubmed |
| pubmed-article:21029821 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21029821 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029821 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21029821 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:21029821 | pubmed:issn | 1879-1913 | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:LoweRobert... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:TershakovecAn... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:BrownW... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:FoodyJoAnne... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:ZieveFranklin... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:Jones-BurtonC... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:AdewaleAdeniy... | lld:pubmed |
| pubmed-article:21029821 | pubmed:author | pubmed-author:FlaimDoreenD | lld:pubmed |
| pubmed-article:21029821 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21029821 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21029821 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21029821 | pubmed:volume | 106 | lld:pubmed |
| pubmed-article:21029821 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21029821 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21029821 | pubmed:pagination | 1255-63 | lld:pubmed |
| pubmed-article:21029821 | pubmed:dateRevised | 2011-3-11 | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:meshHeading | pubmed-meshheading:21029821... | lld:pubmed |
| pubmed-article:21029821 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21029821 | pubmed:articleTitle | Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ?65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). | lld:pubmed |
| pubmed-article:21029821 | pubmed:affiliation | Harvard Medical School, Brigham and Women's, Boston, Massachusetts, USA. jfoody@partners.org | lld:pubmed |
| pubmed-article:21029821 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21029821 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21029821 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21029821 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21029821 | lld:pubmed |
